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Abstract
Tangier Disease (TD) is a rare inherited disorder with approximately 100 
worldwide identified cases. Alpha-lipoprotein deficiency is the main characteristic 
of this disease, associated with a virtual absence of High Density Lipoproteins 
(HDL) in blood. Additional symptoms are mild hypertriglyceridemia, neuropathy 
and enlarged, orange-colored tonsils. Genetically TD is caused by mutations in 
the ABCA1 gene, which prevent the release of cholesterol and phospholipids 
from cells, leading to the accumulation of lipids within cells and body tissues.
In this work a TD patient and his parental heterozygous were examined 
from a proteomics point of view. Plasma as well as proteome and secretome of 
circulating monocytes were analyzed. 
Plasma proteins underlined in TD the imbalance of lipid trafficking and 
metabolism, associated with the stimulation of pro-inflammatory pathways. 
Proteome and secretome of monocytes highlighted an extensive down 
regulation of mitochondrial enzymes and vesicular trafficking agents along with 
a substantial cytoskeletal rearrangement, suggesting a reduced activation state 
of monocytes from TD homozygous patient.
This work is the first proteomics profiling of heterozygous and homozygous 
TD phenotypes and it suggests a TD case as a model to understand general 
mechanisms of lipid transport and metabolism and their linkage to inflammatory 
processes.
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involvement in the progression and/or regression of cardiovascular 
diseases [5]. Due to its central role in the modulation of cholesterol 
homeostasis, ABCA1 is an attractive target for drug development, but 
the molecular actors of the ABCA1 lipid pathway are not completely 
revealed. Studies are needed to understand how lipids are translocated 
across the plasma membrane and to identify associated proteins that 
modulate this pathway. Proteomics studies would help to disclose 
intracellular and secreted factors involved in dysfunction of lipid 
trafficking and in its clinical manifestation suggesting new targets 
for therapeutic interventions that might modulate ABCA1 activity 
assisting the traffic of cholesterol from cells and tissues. 
In this paper, proteomics analyses of monocytes and plasma of a 
TD patient compared with his heterozygous father are reported. The 
clinical characterization, proband’s kindred and plasma lipoprotein 
profiles of these two cases have been already published in Sampietro 
et al. [6] and in Puntoni et al. [7] (a brief description is also presented 
in the Supplementary Information). 
In brief, molecular factors and activation pathways directly 
responsible of the pathological phenotype are highlighted and the 
TD case has been suggested as model to obtain insights in possible 
mechanisms responsible for lipid dysfunctions and eventually, as a 
consequence, for atherosclerosis initiation.
Case Presentation
Tangier Disease (TD) is an autosomal recessive genetic disorder, 
described for the first time in 1961 [1] and characterized by impaired 
HDL-mediated cholesterol efflux and abnormal intracellular lipid 
trafficking and turnover. TD patients accumulate cholesterol in body 
tissues; show a reduced level of HDL, disturbances of nerve functions, 
premature atherosclerosis and a high incidence of Coronary Artery 
Disease (CAD). TD is a rare genetic disorder, with less than 100 
cases reported in the literature, and patients present both alleles of 
ABCA1 gene mutated; this gene encodes a member of the ATP-
Binding Cassette (ABC) transporter family [2, 3]. Carriers of a single 
ABCA1 mutation (heterozygotes) display an intermediate phenotype 
with a 50% reduction in the ABCA1-mediated cell cholesterol efflux 
[4]. Despite the commitment of a unique documented gene, TD is 
characterized by high variability in phenotypic manifestations, either 
qualitatively or quantitatively, in terms of clinical severity and organ 
involvement. In brief there is not a direct correlation between the gene 
mutation and the numerous and various clinical features described in 
TD patients.
ABCA1 is the major responsible transporter for clearing 
cholesterol from macrophages and, since cholesterol accumulation 
in arterial macrophages is atherogenic, this pathway has a clear 
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Proteomics Profiling
TD homozygous proteomics profile was compared with his 
parental heterozygous (for the ABCA1 mutation). This choice was 
suggested by the fact that genetic background is akin and both patients 
are subjected to the same clinical treatments for cardiovascular 
disease, even if the heterozygous is mildly affected. In this way it was 
possible to approximate differences in the proteomics profiles due 
mostly to the different expression of the pathology so as to extrapolate 
factors involved in dyslipidemia as a main cause of early onset of 
atherosclerosis. 
Using a shot-gun proteomics strategy (for details see 
Supplementary Information), we were able to identify 197 proteins in 
depleted plasma samples of both patients (Table S1).
46 plasma proteins (Table 1) were found differentially expressed 
between TD patient and his heterozygous father. In particular 
22 proteins resulted down-regulated and 24 up-regulated in 
homozygous with respect to heterozygous. Among the down-
regulated in the homozygous, 13 different apolipoproteins were 
particularly interesting. In addition, also Paraoxonase 1 has been 
found down-regulated in homozygous patient plasma. This enzyme 
has been suggested to be involved in the protection against oxidative 
modification of lipoproteins and consequently against pivotal 
events leading to atheroma formation [8,9].These results, although 
preliminary, confirm that plasma proteomics can evidence the 
imbalance of lipid trafficking and metabolism in TD, suggesting 
a distinctive characteristic fingerprint, provided with a panel of 
correlated elements. Among the differentially expressed proteins 
some are linked to inflammation, such as Orosomucoid 1 and 2 
and Kininogen 1. Kininogen 1 has been found over expressed in 
plasma of homozygous patient and it seems to be a key mediator 
of inflammation [10]. On the other hand, Orosomucoid 1 and 2 
resulted down-expressed in homozygous plasma and, besides being 
involved in pro-inflammatory responses [11,12], they also exert a 
possible role as lipid carrier in blood circulation [13,14]. Moreover 
and of note, 4 differentially expressed proteins are related to different 
growth factor pathways: Vasorin may act as inhibitor of TGF-
beta signaling [15], Insulin like Growth Factor Binding Protein 4 
(IGFBP4) and Insulin-like Growth Factor-Binding Protein Complex 
Acid Labile Subunits (IGFALS) are key elements of the IGF pathway 
and Hepatocyte Growth Factor Activator (HGFA) that seems to play 
role in inflammatory processes [16]. In conclusion, plasma proteome 
of TD patient proves a general dysregulation of lipid trafficking and 
metabolism, associated with the stimulation of growth factor and 
inflammatory pathways.  
Figure 1: Monocyte proteome (A) and secretome (B). Identified proteins were classified according to their localization.
Figure 2: Monocyte secreted proteins classified according to the intracellular 
pathways (classically or non classically secreted) as predicted by SecretomeP 
Server.
Figure 3: Interaction network of differentially expressed proteins in monocyte 
proteome. Top scoring and significant proteins were submitted to String 
database and resulted image was adapted. 
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Although ABCA1 is expressed in many tissues, the accumulation 
of cholesterol in TD interests mostly macrophages [17]. An early 
event in atherogenesis is the recruitment of monocytes from the 
peripheral blood vessel intima as a consequence of high amounts of 
lipids and high levels of protein oxidation. Monocytes transmigrate 
into the vessel wall and differentiate into macrophages. Macrophages 
are well known to exert an important role in atheroprotection/
atheroformation, removing excess of cholesterol from tissues. 
Reverse Cholesterol Transport (RCT) is a pathway responsible of 
the transport of accumulated cholesterol from the vessel wall to 
the liver for excretion, this process preventing inflammation and 
atherosclerosis [18]. Many studies indicate that the inflammatory 
process impairs RCT [19]. ABCA1 is the major cholesterol efflux 
system in macrophages, it plays a crucial role in the modulation 
of inflammatory response [20] and in mice its knockout increases 
inflammatory cell infiltration [21]. Monocytes are the circulatory 
Accession Peak Name Protein names Homo vs Hetero p-value
Log (Fold 
Change)
Q04756 HGFA_HUMAN Hepatocyte growth factor activator DOWN 4.55E-05 0.847184
P02647 APOA1_HUMAN Apolipoprotein A-I DOWN 0.00017 0.771506
P02654 APOC1_HUMAN Apolipoprotein C-I DOWN 0.00054 0.726025
P00738 HPT_HUMAN Haptoglobin-relatedprotein DOWN 0.00072 0.350024
P00915 CAH1_HUMAN Carbonicanhydrase 1 DOWN 0.00186 0.847092
P02652 APOA2_HUMAN Apolipoprotein A-II DOWN 0.00255 0.695098
P27169 PON1_HUMAN Serum paraoxonase/arylesterase 1 (PON 1) DOWN 0.00291 0.483498
P02042 HBD_HUMAN Hemoglobinsubunit delta (Delta-globin) DOWN 0.00394 0.362336
P00739 HPTR_HUMAN Haptoglobin (Zonulin) DOWN 0.00401 0.513322
O75636 FCN3_HUMAN Ficolin-3 (Collagen/fibrinogen domain-containing lectin 3 p35) DOWN 0.00597 0.330745
P00746 CFAD_HUMAN Complement factor D  (Adipsin) DOWN 0.00684 0.503916
O95445 APOM_HUMAN Apolipoprotein M DOWN 0.00827 1.142308
P19652 A1AG2_HUMAN Alpha-1-acid glycoprotein 2 (Orosomucoid-2) DOWN 0.01005 0.435858
P22792 CPN2_HUMAN Carboxypeptidase N subunit 2 DOWN 0.01067 0.552475
P35542 SAA4_HUMAN Serum amyloid A-4 protein DOWN 0.01249 0.63467
O14791 APOL1_HUMAN Apolipoprotein L1 DOWN 0.01259 0.567598
P00488 F13A_HUMAN Coagulation factor XIII A chain DOWN 0.01438 0.720657
Q6UXB8 PI16_HUMAN Peptidase inhibitor 16 DOWN 0.01584 1.509586
P02775 CXCL7_HUMAN Platelet basic protein (PBP) DOWN 0.02249 0.664629
P05090 APOD_HUMAN Apolipoprotein D DOWN 0.02422 0.332828
P02656 APOC3_HUMAN Apolipoprotein C-III DOWN 0.02636 0.844092
P80108 PHLD_HUMAN Phosphatidylinositol-glycan-specific phospholipase D DOWN 0.02891 0.720058
O43866 CD5L_HUMAN CD5 antigen-like (IgM-associated peptide) UP 4.06E-05 -0.6351
P01871 IGHM_HUMAN Ig mu chain C region UP 0.00013 -0.52174
P02768 ALBU_HUMAN Serumalbumin UP 0.0014 -0.50844
P06331 HV209_HUMAN Ig heavy chain V-II region ARH-77 UP 0.00152 -0.60634
P04208 LV106_HUMAN Ig lambda chain V-I region WAH UP 0.00274 -0.87145
P01834 IGKC_HUMAN Ig kappa chain C region UP 0.00321 -0.35637
P35858 ALS_HUMAN
Insulin-like growth factor-binding protein complex acid labile subunit 
(ALS)
UP 0.00506 -0.37728
P01042 KNG1_HUMAN Kininogen-1 (Alpha-2-thiol proteinase inhibitor) UP 0.00524 -0.32611
P04430 KV122_HUMAN Ig kappa chain V-I region BAN UP 0.00608 -0.61736
P01591 IGJ_HUMAN Immunoglobulin J chain UP 0.00997 -1.05921
P01743 HV102_HUMAN Ig heavy chain V-I region HG3 UP 0.01589 -0.81718
P06316 LV107_HUMAN Ig lambda chain V-I region BL2 UP 0.01694 -2.00561
P04220 MUCB_HUMAN Ig mu heavy chain disease protein (BOT) UP 0.01833 -0.36182
P01876 IGHA1_HUMAN Ig alpha-1 chain C region UP 0.01903 -0.30019
P04433 KV309_HUMAN Ig kappa chain V-III region VG (Fragment) UP 0.02037 -0.62005
P01880 IGHD_HUMAN Ig delta chain C region UP 0.02129 -0.64278
P01859 IGHG2_HUMAN Ig gamma-2 chain C region UP 0.02168 -0.64733
P01861 IGHG4_HUMAN Ig gamma-4 chain C region UP 0.02441 -0.66096
P18428 LBP_HUMAN Lipopolysaccharide-bindingprotein UP 0.02811 -0.69375
P13645 K1C10_HUMAN Keratin, type I cytoskeletal 10 UP 0.02953 -0.64284
P01857 IGHG1_HUMAN Ig gamma-1 chain C region UP 0.03532 -0.37459
P01717 LV403_HUMAN Ig lambda chain V-IV region Hil UP 0.03595 -1.08395
P03952 KLKB1_HUMAN Plasma kallikrein UP 0.03806 -0.59386
O00187 MASP2_HUMAN Mannan-binding lectin serine protease 2 UP 0.04597 -1.06298
Table 1: Differentially expressed proteins in plasma samples.
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Accession Peak Name Protein name
Homo
vs
Hetero
p-value Log (Fold Change)
P08311 CATG_HUMAN Cathepsin G DOWN 0.00509 -0.81137
O00299 CLIC1_HUMAN Chlorideintracellularchannelprotein 1 DOWN 0.00429 -0.98615
P06703 S10A6_HUMAN Protein S100-A6 DOWN 0.03129 -0.71595
Q92930 RAB8B_HUMAN Ras-related protein Rab-8B DOWN 0.00329 -1.00065
P61006 RAB8A_HUMAN Ras-related protein Rab-8A DOWN 0.02228 -1.4238
P61026 RAB10_HUMAN Ras-relatedprotein Rab-10 DOWN 0.00993 -0.81693
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein DOWN 0.0011 -0.61458
P06396 GELS_HUMAN Gelsolin DOWN 0.00136 -0.64524
P06753 TPM3_HUMAN Tropomyosin alpha-3 chain DOWN 0.03406 -0.55569
P31146 COR1A_HUMAN Coronin-1A DOWN 0.01454 -0.54048
P14625 ENPL_HUMAN Endoplasmin DOWN 0.00317 -0.63045
P84077 ARF1_HUMAN ADP-ribosylationfactor 1 DOWN 0.00311 -0.87542
P05164 PERM_HUMAN Myeloperoxidase DOWN 0.00178 -0.81517
P08575 PTPRC_HUMAN Receptor-type tyrosine-protein phosphatase C DOWN 0.03603 -0.96159
P04179 SODM_HUMAN Superoxidedismutase [Mn], mitochondrial DOWN 0.02356 -1.86513
P09622 DLDH_HUMAN Dihydrolipoyldehydrogenase, mitochondrial DOWN 0.00493 -1.1493
P10606 COX5B_HUMAN Cytochrome c oxidasesubunit 5B, mitochondrial DOWN 0.00089 -1.5417
P10809 CH60_HUMAN 60 kDa heat shock protein, mitochondrial DOWN 0.00071 -1.05006
P61604 CH10_HUMAN 10 kDa heat shock protein, mitochondrial DOWN 0.00384 -1.08989
Q16836 HCDH_HUMAN Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial DOWN 0.02882 -1.51385
P06576 ATPB_HUMAN ATP synthase subunit beta, mitochondrial DOWN 0.02171 -0.65835
P30048 PRDX3_HUMAN Thioredoxin-dependent peroxide reductase, mitochondrial DOWN 0.02955 -1.02142
Q13011 ECH1_HUMAN Delta(3,5)-Delta(2,4)-dienoyl-CoAisomerase, mitochondrial DOWN 0.0026 -1.13024
P55084 ECHB_HUMAN Trifunctional enzyme subunit beta, mitochondrial DOWN 0.00162 -1.0893
Q07021 C1QBP_HUMAN
Complement component 1 Q subcomponent-binding protein, 
mitochondrial DOWN 0.01677 -1.11609
Q14240 IF4A2_HUMAN Eukaryotic initiation factor 4A-II DOWN 0.02237 -1.11038
P63241 IF5A1_HUMAN Eukaryotic translation initiation factor 5A-1 DOWN 0.03193 -0.85348
P05154 IPSP_HUMAN Plasma serine proteaseinhibitor DOWN 0.02319 -1.1857
P01023 A2MG_HUMAN Alpha-2-macroglobulin DOWN 0.01839 -0.85005
P02765 FETUA_HUMAN Alpha-2-HS-glycoprotein DOWN 0.00435 -1.34102
P61626 LYSC_HUMAN Lysozyme C DOWN 0.01812 -1.54991
P04264 K2C1_HUMAN Keratin, type II cytoskeletal 1 UP 0.00435 0.773886
P60174 TPIS_HUMAN Triosephosphateisomerase UP 0.04817 0.537814
P00558 PGK1_HUMAN Phosphoglyceratekinase 1 UP 0.00521 0.614203
P40121 CAPG_HUMAN Macrophage-cappingprotein UP 0.03962 0.815598
P00488 F13A_HUMAN Coagulation factor XIII A chain UP 0.0026 0.830138
P13647 K2C5_HUMAN Keratin, type II cytoskeletal 5 UP 0.031 0.954622
Q9NZT1 CALL5_HUMAN Calmodulin-likeprotein 5 UP 0.01543 0.843285
P07737 PROF1_HUMAN Profilin-1 UP 0.0115 0.177598
P35527 K1C9_HUMAN Keratin, type I cytoskeletal 9 UP 0.00304 1.021316
P62328 TYB4_HUMAN Thymosin beta-4 UP 0.00614 1.665154
P61158 ARP3_HUMAN Actin-relatedprotein 3 UP 0.011 0.967938
P08514 ITA2B_HUMAN Integrinalpha-IIb UP 0.03896 1.792178
P26447 S10A4_HUMAN Protein S100-A4 UP 0.0369 2.142443
Q9HBT7 ZN287_HUMAN Zinc finger protein 287 UP 0.02335 1.781582
Table 2: Differentially expressed proteins in monocyte proteome samples.
precursors of macrophages and play a central role under several 
pathophysiological conditions, particularly when inflammatory 
reactions are involved. For these reasons we were interested in 
analyzing the proteome and the secretome of monocytes from a TD 
patient and to compare these profiles with those of the heterozygous 
father.
Monocyte proteome analysis identified 198 proteins while 
128 proteins were found in secretome. Proteins are reported in 
(Supplementary Data Table S2 and Table S3 respectively). They 
were classified based on their localization (Figure 1) using Uniprot 
database (www.uniprot.com), while the secretome proteins were 
also subdivided, according to the secretion pathway (Figure 2), in 
classically or non classically secreted, as predicted by the SecretomeP 
2.0 Server (http://www.cbs.dtu.dk/services/SecretomeP/). 
Monocyte whole proteome analysis brought to the identification 
of 198 proteins, of which, so much as 47 resulted differentially 
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Accession Peak Name Protein Name
Homo
vs
Hetero
p-value Log (Fold Change)
P61160 ARP2_HUMAN Actin-relatedprotein 2 DOWN 0.00059 -0.73265
P31146 COR1A_HUMAN Coronin-1A DOWN 0.02114 -0.39996
Q9Y490 TLN1_HUMAN Talin-1 DOWN 0.02877 -0.32292
P00558 PGK1_HUMAN Phosphoglyceratekinase 1 DOWN 0.02932 -0.41883
P07996 TSP1_HUMAN Thrombospondin-1 DOWN 0.04812 -0.65607
P07437 TBB5_HUMAN Tubulin beta chain DOWN 0.04965 -0.35121
P62937 PPIA_HUMAN Peptidyl-prolylcis-trans isomerase A UP 0.00154 0.465786
O15145 ARPC3_HUMAN Actin-relatedprotein 3 UP 0.0023 0.687822
P60842 IF4A1_HUMAN Eukaryotic initiation factor 4A-I UP 0.00544 0.403022
P60660 MYL6_HUMAN Myosin light polypeptide 6 UP 0.00622 0.860975
Q01518 CAP1_HUMAN Adenylylcyclase-associatedprotein 1 UP 0.01958 0.294693
Q9NY33 DPP3_HUMAN Dipeptidylpeptidase 3 UP 0.02472 0.360369
P32119 PRDX2_HUMAN Peroxiredoxin-2 UP 0.02762 0.540569
P50395 GDIB_HUMAN Rab GDP dissociation inhibitor beta UP 0.02791 0.965144
P61978 HNRPK_HUMAN Heterogeneousnuclearribonucleoprotein K UP 0.03703 0.474348
P08670 VIME_HUMAN Vimentin UP 0.04041 0.285031
Table 3: Differentially expressed proteins in monocyte secretome samples.
expressed (Table 2). Four principal functional groups may be 
underlined: a)- cytoskeleton organization (Coronin 1, Profilin 1, 
Tropomyosin 3, S100A6, Gelsolin, Thymosin beta4, Actin-related 
protein 3 and Macrophage-capping protein), b)- mitochondrial 
functions(Superoxide dismutase, Cytochrome C oxidase, ATP 
synthase beta, Thioredoxin-dependent peroxide reductase, Heat 
shock cognate 71 protein, Heat shock 60 kDa protein, Heat shock 
10 kDa protein, Dihydroprolyl dehydrogenase, Hydroxyacyl-
coenzyme A dehydrogenase, Trifunctional enzyme subunit beta, 
Complement component 1 Q subcomponent-binding protein), 
c)- vesicular trafficking regulation (RAS-related protein Rab-8B, 
RAS-related protein Rab-8A, RAS-related protein Rab-10, ADP-
ribosylation factor 1) and d)-defense activities  (Myeloperoxidase, 
Cathepsin G, Lysozyme C, Plasma serine protease inhibitor, 
Alpha-2-macroglobulin). It is interesting to note that all groups 
are somehow related to monocyte-macrophage transition since 
differentiation is triggered by mitochondrial functions, induces a 
dramatic rearrangement of cytoskeleton due to increasing motility 
and enhances vesicular trafficking for more intense intra- and 
intercellular interactions, these including also defense strategies. 
Indeed, mitochondrial functions produce Reactive Oxygen 
Species (ROS), which are recognized triggers of monocyte activation 
[22]. Normally, the diffusion of ROS and damaged mitochondrial 
contents into the cytosol is prevented by autophagy. During 
autophagy cytosolic constituents are enclosed within a double-layered 
lipid vesicle addressed to fuse with lysosomes for degradation and 
recycling of the internal contents. Impaired autophagy may interfere 
with mitochondrial turnover [23]. 
In brief, the extensive down regulation of mitochondrial enzymes 
and vesicular trafficking agents along with cytoskeletal and defense 
proteins in monocyte proteome (Figure 3) suggest a reduced 
activation ability of monocytes from TD homozygous patient.
As expected, a lower number of proteins were identified in the 
secretome (128) and of these only 16 resulted differentially released 
within 24 h (Table 3). The majority (8 out of 16) are actin binding or 
related factors, underlining a reassessment of monocyte cytoskeleton. 
Conclusion
In conclusion, it was possible to obtain a preliminary plasma 
fingerprint and a monocyte molecular map of Tangier disease. This 
study could be preparatory for deeper and more specific analyses that 
could help to understand general mechanisms of lipid transport and 
metabolism and their linkage to inflammatory processes.
Limitation of this work is the difficulty to establish if the results 
obtained with a TD patient can be extrapolated to other TD patients, 
due to the infrequence of this genetic disorder. Nevertheless, this 
case can be exploited as model for the study of general, common 
mechanisms in cell biology. 
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